Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
Earnings Data
Report Date
Mar 05, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted a successful launch of IBTROZI with strong adoption and expansion in markets outside the U.S., alongside robust financial performance. However, challenges related to high costs and strategic decisions in the IDH1 program were noted. The positive growth and approval metrics for IBTROZI outweigh these challenges.Company Guidance
Successful Launch of IBTROZI
IBTROZI received full FDA approval on June 11, and in its first full quarter as a commercial stage company, Nuvation Bio reported 204 new patients started IBTROZI, equivalent to over 15 new patient starts per week.
Strong Efficacy and Safety Profile of IBTROZI
IBTROZI demonstrated a median duration of response of 50 months in TKI-naive patients, with a 66% confirmed intracranial response rate in patients with brain metastases who were TKI pretreated.
Regulatory and Market Expansion
IBTROZI received regulatory approval in Japan and expanded access to the ROS1-positive non-small cell lung cancer market outside the U.S.
Robust Financial Performance
Nuvation Bio reported $13.1 million in total revenue in the first quarter as a commercial stage company, including $7.7 million in net product revenue from IBTROZI.
Expansion of Patient Access and Coverage
As of the end of the quarter, IBTROZI was covered by payers representing more than 80% of covered lives, up from 58% just two months prior.
NUVB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NUVB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | $5.17 | $4.83 | -6.58% |
Aug 07, 2025 | $2.35 | $2.34 | -0.43% |
May 07, 2025 | $2.04 | $2.10 | +2.94% |
Mar 06, 2025 | $1.89 | $2.02 | +6.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nuvation Bio (NUVB) report earnings?
Nuvation Bio (NUVB) is schdueled to report earning on Mar 05, 2026, After Close (Confirmed).
What is Nuvation Bio (NUVB) earnings time?
Nuvation Bio (NUVB) earnings time is at Mar 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NUVB EPS forecast?
NUVB EPS forecast for the fiscal quarter 2025 (Q4) is -0.1.